MEN1-associated primary hyperparathyroidism in the Spanish Registry: clinical characterictics and surgical outcomes.
MEN1 gene
hypoparathyroidism
multiple endocrine neoplasia type 1
parathyroidectomy
primary hyperparathyroidism
Journal
Endocrine connections
ISSN: 2049-3614
Titre abrégé: Endocr Connect
Pays: England
ID NLM: 101598413
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
15
09
2019
accepted:
23
09
2019
pubmed:
27
9
2019
medline:
27
9
2019
entrez:
27
9
2019
Statut:
ppublish
Résumé
Primary hyperparathyroidism is the most frequent manifestation of multiple endocrine neoplasia type 1 (MEN1) syndrome. Bone and renal complications are common. Surgery is the treatment of choice, but the best timing for surgery is controversial and predictors of persistence and recurrence are not well known. Our study describes the clinical characteristics and the surgical outcomes, after surgery and in the long term, of the patients with MEN1 and primary hyperparathyroidism included in the Spanish Registry of Multiple Endocrine Neoplasia, Pheochromocytomas and Paragangliomas (REGMEN). Eighty-nine patients (49 men and 40 women, 34.2 ± 13 years old) were included. Sixty-four out of the 89 underwent surgery: a total parathyroidectomy was done in 13 patients, a subtotal parathyroidectomy in 34 and a less than subtotal parathyroidectomy in 15. Remission rates were higher after a total or a subtotal parathyroidectomy than after a less than subtotal (3/4 and 20/22 vs 7/12, P < 0.05), without significant differences in permanent hypoparathyroidism (1/5, 9/23 and 0/11, N.S.). After a median follow-up of 111 months, 20 of the 41 operated patients with long-term follow-up had persistent or recurrent hyperparathyroidism. We did not find differences in disease-free survival rates between different techniques, patients with or without permanent hypoparathyroidism and patients with different mutated exons, but a second surgery was more frequent after a less than subtotal parathyroidectomy.
Identifiants
pubmed: 31557724
doi: 10.1530/EC-19-0321
pii: EC-19-0321.R2
pmc: PMC6826168
doi:
pii:
Types de publication
Journal Article
Langues
eng
Pagination
1416-1424Références
Ann Surg. 2012 Jun;255(6):1171-8
pubmed: 22470073
J Bone Miner Res. 2010 Nov;25(11):2382-91
pubmed: 20499354
World J Surg. 2016 Mar;40(3):615-21
pubmed: 26541865
J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
pubmed: 22723327
Chirurg. 2004 Sep;75(9):900-6
pubmed: 15168030
Br J Surg. 2010 Oct;97(10):1528-34
pubmed: 20629112
Surgery. 2002 Dec;132(6):1119-24; discussion 1124-5
pubmed: 12490864
Surgery. 2013 Jul;154(1):101-5
pubmed: 23809488
Eur J Endocrinol. 2015 Aug;173(2):G1-20
pubmed: 26160136
J Clin Endocrinol Metab. 2014 Oct;99(10):3595-606
pubmed: 25162669
World J Surg. 2016 Dec;40(12):2964-2969
pubmed: 27402205
World Health Organ Tech Rep Ser. 1994;843:1-129
pubmed: 7941614
Endocrine. 2017 Nov;58(2):349-359
pubmed: 28132167
Ann Surg. 2008 Mar;247(3):501-10
pubmed: 18376196
Clinics (Sao Paulo). 2012;67 Suppl 1:99-108
pubmed: 22584713
Arch Surg. 1999 Oct;134(10):1119-23
pubmed: 10522858
World J Surg. 2011 Sep;35(9):1993-2005
pubmed: 21713580
Ann Surg Oncol. 2016 Feb;23(2):416-23
pubmed: 26542588
Clinics (Sao Paulo). 2012;67 Suppl 1:141-4
pubmed: 22584719
Eur J Surg. 2001 Mar;167(3):173-8
pubmed: 11316400
Clin Endocrinol (Oxf). 2010 Apr;72(4):462-8
pubmed: 19650788
J Bone Miner Res. 2009 Aug;24(8):1404-10
pubmed: 19309299
Langenbecks Arch Surg. 2015 Dec;400(8):867-86
pubmed: 26450137
J Endocrinol Invest. 2012 Jun;35(6):573-9
pubmed: 21791969
Orphanet J Rare Dis. 2018 Nov 14;13(1):205
pubmed: 30428914
Int J Endocrinol. 2010;2010:928383
pubmed: 21318141
World J Surg. 2001 Jul;25(7):886-90
pubmed: 11572029